BioSpace News Archive

Study Being Led by Leading Ocular Oncologist, Carol L. Shields, M.D., Director, Ocular Oncology Service, Wills Eye Hospital

Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, announced that the company will present at the following virtual investor conferences in September.

Omeros Corporation announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week.

Company is committed to evaluating use of the broad-spectrum antiviral in the early treatment setting of COVID-19 to shorten the time to clinical recovery in adult patients with mild to moderate symptoms Investigators plan to recruit 826 participants in the randomized, placebo-controlled trial Study subset will focus on favipiravir’s potential to reduce viral shedding, diminishing the period of infectiousness HALIFAX, Nova Scotia--( BU

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced that management is scheduled to present at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is being held from September 14-16, 2020.

VBL Therapeutics (Nasdaq: VBLT ), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). VBL’s study is being presented at the MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting . Data show that VBL’s anti-MOSPD2 mAbs significantly inhibited migration of monocytes isolate

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the presentation of five scientific posters highlighting data regarding BELBUCA at the 14 th Annual PAINWeek 2020 National Conference on Pain Management taking place virtually September 11-13, 2020. Poster Presentations: A Phase I Placebo-Controlled Trial Compar

With much of the COVID-19 response to date focusing on human-to-human transmission of the virus, the importance of environmental monitoring remains largely unaddressed.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced that CEO, John Climaco , will present virtually at the H.C. Wainwright & Co. 22 nd Annual Global Inv

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that new data evaluating the oral investigational agent dubermatinib (TP-0903), an AXL kinase inhibitor, will be presented at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress, being held September 19